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Parkinson’s disease (PD) is a neurodegenerative disorder predominantly affecting the elderly. The aetiology of the disease is
not known, but age and environmental factors play an important role. Although more than a dozen gene mutations associated
with familial forms of Parkinson’s disease have been described, fewer than 10% of all cases can be explained by genetic
abnormalities. The molecular basis of Parkinson’s disease is the loss of dopamine in the basal ganglia (caudate/putamen) due to
the degeneration of dopaminergic neurons in the substantia nigra, which leads to the motor impairment characteristic of the
disease. Methamphetamine is the second most widely used illicit drug in the world. In rodents, methamphetamine exposure
damages dopaminergic neurons in the substantia nigra, resulting in a significant loss of dopamine in the striatum. Biochemical
and neuroimaging studies in humanmethamphetamine users have shown decreased levels of dopamine and dopamine transporter
as well as prominent microglial activation in the striatum and other areas of the brain, changes similar to those observed in PD
patients. Consistent with these similarities, recent epidemiological studies have shown that methamphetamine users are almost
twice as likely as non-users to develop PD, despite the fact thatmethamphetamine abuse and PD have distinct symptomatic profiles.
1. Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer’s disease, affecting
an estimated 7 to 10 million people worldwide. Incidence of
the disease increases with age. PD usually affects people over
the age of 50, but an estimated 4% of PD cases is diagnosed
before the age of 50. Early in the course of the disease,
the most obvious symptoms are movement-related. These
include shaking, rigidity, slowness of movement, and diffi-
culty with walking and gait. Later, cognitive and behavioral
problems may arise, with dementia commonly occurring in
the advanced stages of the disease. Other symptoms include
sensory, sleep, and emotional problems. PD is caused by
degeneration of midbrain dopaminergic neurons that project
to the striatum. The loss of striatal dopamine is responsible
for the major symptoms of the disease. Although a small
proportion of cases can be attributed to known genetic
factors, most cases of PD are idiopathic. While the aetiology
of dopaminergic neuronal demise is elusive, a combination
of genetic susceptibilities, age, and environmental factors
seems to play a critical role [1]. Dopamine degeneration
process in PD involves abnormal protein handling, oxidative
stress, mitochondrial dysfunction, excitotoxicity, apoptotic
processes, and microglial activation/neuroinflammation.
2. Epidemiology and Pharmacology of
Methamphetamine Use
Methamphetamine is an addictive, highly water-soluble CNS
(central nervous system) stimulant. It belongs to the group of
synthetic drugs chemically related to amphetamine; however,
its effects on the CNS are much more pronounced than those
of the parent compound. Abuse of these illegal psychostimu-
lants has become an international public health problem,with
an estimated 14 to 52 million amphetamine-type stimulant
users worldwide, exceeding the total number of cocaine
2 Parkinson’s Disease
abusers and second only to the number of cannabis abusers
[2]. Hydrochloride methamphetamine, known as “meth” or
“speed”, can be found in the powder state, compressed into
tablets or capsules of 10 to 15mg, or in a purer crystalline
form.
Methamphetamine is taken by abusers for several desired
effects: euphoria and a sense of well-being, increased physical
activity and energy, and decreased anxiety. These effects
appear immediately after drug consumption and can last for
several hours. They may be accompanied by acute adverse
effects such as increased blood pressure and heart rate, which
may cause irreversible damage to blood vessels in the brain,
resulting in cerebrovascular accidents, stroke, and death.
Methamphetamine also produces hyperthermia, mydriasis
(pupil dilation), flushing, tremors, trismus and bruxism,
muscle tension, loss of appetite or anorexia, and loss of
pleasure in food intake.
Methamphetamine is an addictive drug, and abusers
may rapidly develop tolerance.Themost common symptoms
of chronic methamphetamine abuse are temporomandibu-
lar joint syndrome, dental erosion, and myofacial pain
[3]. Long-term use also produces lack of appetite, weight
loss, accelerated aging, nose-bleeding problems, nonhealing
wounds, and tooth decay and fracture known as “Meth
mouth”. Psychiatric symptoms include anxiety, depression,
increased aggression, social isolation, psychosis, mood dis-
turbances, and psychomotor dysfunction. Long periods of
high consumption can cause paranoid psychosis. In addition,
deficits in attention, working memory, and decision making
have been detected in chronic methamphetamine addicts.
Withdrawal from methamphetamine can cause irritability,
fatigue, impaired social functioning, and intense craving for
the drug.There is evidence that the negative neuropsychiatric
consequences of methamphetamine abuse are due, at least in
part, to drug-induced neuropathological changes in the brain
[4].
3. Methamphetamine Toxicity in
Experimental Animals
3.1. Methamphetamine Toxicity in the Striatum. Animal stud-
ies have shown that methamphetamine can cause long-term
dopamine terminal damage as well as dopamine neuronal
body loss. In rodents, repeated administration of metham-
phetamine causes a decrease in dopaminergic markers such
as tyrosine hydroxylase (TH) and dopamine transporter
(DAT) (see Figure 1), accompanied by a reduction in TH
activity, reduced levels of dopamine (DA) and its metabo-
lites (3,4-dihidroxyphenylacetic, DOPAC, homovanillic acid,
HVA), and decreased levels of vesicular monoamine trans-
porter 2 (VMAT2).These effects occur primarily in the stria-
tum (caudate-putamen), but as well in the cortex, thalamus,
hypothalamus, and hippocampus [5–10]. Methamphetamine
induces neurotoxicity in a dose-dependent manner [11] as
do other amphetamine-derivatives like MDMA [12, 13].
Although partial recovery of TH and DAT fibers occurs
after methamphetamine administration, methamphetamine-
induced neurotoxicity is persistent. In mice, the greatest
dopaminergic fiber loss is seen 1 day after methamphetamine
administration (Figure 1). Neurotoxic effects persist for more
than seven days after methamphetamine exposure [5, 14,
15] and one month after MDMA exposure [13]. Drugs that
induce parkinsonian symptoms and TH loss such as MPTP
in mice also show a partial recovery with time in nonhuman
monkeys and mice [16]. The time courses and degrees of
TH and DAT fiber recovery after methamphetamine or after
MDMA exposure are similar, suggesting terminal regrowth,
as these two proteins are independently regulated (Figure 1).
In addition, there is partial recovery of dopamine levels in
the striatum [5, 7, 12], strongly suggesting that the regrown
terminals are functional. The mechanisms responsible for
the partial recovery are not known, but might involve com-
pensatory sprouting and branching as has been reported for
regrowth following MPTP-induced damage [17]. Dopamine
terminal recovery has also been described in rhesus monkeys
and velvet monkeys, although it appears to occur on a
slower timescale than in mice: methamphetamine-induced
dopaminergic damage persists for more than 12 weeks in
velvet monkeys and more than 3 years in rhesus monkeys
[11, 18], demonstrating the persistence of methamphetamine-
induced brain damage.
Interestingly, striatal TH cells that appear in Parkinsonian
brains [19] and in 6-OHDA- and MPTP-denervated animals
[20, 21] are also evident after methamphetamine treatment
(unpublished observations). These TH neurons only appear
in severely dopamine-denervated striatal areas and, therefore,
represent evidence in support of the strong denervation that
methamphetamine use can cause.
3.2. Methamphetamine Toxicity in the Substantia Nigra. In
addition to TH fiber loss, methamphetamine administration
produces dopamine cell body loss in the substantia nigra
pars compacta (SNpc), as indicated by stereological counts in
TH-stained SN sections from mice treated with 3 metham-
phetamine injections (5mg/kg) at 3-hour intervals. These
counts show 20 to 25% dopaminergic cell loss, measured at
different time points after methamphetamine exposure. The
observed pattern of TH-stained neuron loss is very similar
to the pattern of Nissl-stained neuron loss, indicating that
neuronal loss is specific to dopaminergic neurons. Dopamine
cell body loss was confirmed via staining with Fluoro-Jade,
a general marker of neuronal degeneration that fluoresces
after administration of knowndopaminergic toxins such as 6-
OHDA andMPTP [22]. Fluoro-Jade stains scattered neurons
degenerated in the SNpc after methamphetamine treatment.
It is possible that the lack of complete recovery of TH fibers
in the striatum is related to the loss of dopaminergic neurons
in the SNpc [5, 7, 15, 23, 24], resembling what occurs in
Parkinson’s disease [16].
3.3. Neurotoxicity Pattern of Methamphetamine. As in PD, in
which the nucleus accumbens is more resistant to dopamine
loss than the putamen [25, 26], methamphetamine-induced
dopaminergic loss occurs mainly in the nigrostriatal
dopaminergic pathway, while the mesolimbic pathway
is more resistant [6]. Moreover, the two functional and
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Figure 1: Time-course of TH and DAT fiber lost change after methamphetamine administration. Photomicrographs of striatal sections from
mice treated with saline or METH stained for TH and DAT to illustrate the loss (1 day) and the partial recovery (7 days) of dopamine fibers
that occur after methamphetamine administration. Animals were killed 1 and 7 days after treatment. Bar indicates 500 𝜇m.
cytoarchitectonic compartments of the striatum, the
striosomes and matrix, have different vulnerabilities to
methamphetamine. Striosomes, which are connected
with the limbic system and functionally associated with
reward-related and emotional behaviours [27, 28], are more
vulnerable to methamphetamine-induced dopaminergic
terminal loss than the matrix (Figure 2; see also [6]), which
is connected to sensorimotor regions of the brain closely
associated with motor functions [29]. Similarly, greater
striatal damage is observed in the striosomes than the
matrix in experimental animals following the administration
of other neurotoxins such as MDMA [12], MPTP [30],
or quinolinic acid [31]. It is also seen in the early stages of
Huntington’s disease [32] and following ischemia/reperfusion
injury [33, 34]. This pattern of neurotoxicity is inversely
correlated with SOD (superoxide dismutase) expression
in the striatum, suggesting that striosomes, which have
lower levels of SOD expression than the matrix, are more
vulnerable because they have less antioxidant capacity [6, 12].
3.4. Molecular Mechanisms of Methamphetamine Induced-
Neurotoxicity. Although the exact molecular mechanisms
of neuronal body loss are not known, there is evidence
to suggest the coexistence of different types of cell death,
including apoptosis (indicated by the presence of apoptotic-
and AIF-positive-cell bodies) and necrosis (indicated by the
morphology of neurons stained with hematoxylin-eosin).
Increasing evidence demonstrates that methamphetamine
and MDMA induce an increase in lipid peroxidation and
DNA oxidation as well as increased levels of oxidative stress
markers such as hydroxyl radical producing neurotoxicity
[35]. Methamphetamine increases expression of nNOS/iNOS
(Figure 3) indicating increased synthesis of neuronal nitric
oxide [5, 7, 15], which combines with superoxide radicals
to form peroxynitrite, a strong oxidant and a major neuro-
toxin [36]. Induction of nNOS/iNOS by methamphetamine
or MDMA (Figure 3) constitutes part of the mechanism
of methamphetamine damage, as selective inhibition or
genetic inactivation of nNOS and overexpression of cupper
zinc superoxide dismutase (CuZnSOD), an enzyme that
catalyzes the dismutation of superoxide into oxygen and
hydrogen peroxide, prevent methamphetamine neurotoxic-
ity [23, 37, 38]. Although methamphetamine increases iNOS
expression in the striatum (see Figure 3) [5, 6], there is no
basis for supposing the involvement of glial nitric oxide in
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Figure 2: TH- and DAT-ir loss is predominant in striosomes. Serially adjacent sections from a mouse treated with METH stained for TH
(A), MOR-1 (B), and DAT (C). Most striatal TH weak patches matched DAT weak patches. These areas corresponded with striosomes as
demonstrated by MOR-1 immunostaining. A󸀠–C󸀠 show an example of a striosome at higher magnification. Bar indicates 500 𝜇m (A–C) and
200 𝜇m, (A–C󸀠). Modified from Granado et al. [6].
methamphetamine-induced toxicity, but it is interesting to
note that mice deficient in iNOS have increased resistance to
methamphetamine-induced dopamine neuron damage [39].
The neurotoxic effects of methamphetamine on the
dopaminergic system are accompanied by activation of
astroglia and microglia in the same areas [5, 7, 14, 15,
39–41] being strongest in the striatum (Figure 4), the area
with biggest toxicity. Glial cells are not activated in the
nucleus accumbens, which is not much damaged (Figure 4).
In mice, glial activation in striatum and in substantia nigra
occurs shortly after methamphetamine administration, as
indicated by a significant increase inMac-1 (a marker of reac-
tive microglia) 24 hours after methamphetamine exposure
(Figure 4), and prominent increases in GFAP (a marker of
reactive gliosis in response to injury) occur 3–7 days after
treatment [5, 15].The extent of these glial reactions correlates
with the observed severity of neurotoxicity [5, 7, 15].
The dopaminergic system is also involved in this toxicity,
as demonstrated in various mutant mice in which inactiva-
tion of DAT [42], dopamine D1 receptors [5] or D2 receptors
[7] affords a significant protection against methamphetamine
toxicity [43]. Administration of THC prevents dopaminergic
toxicity after MDMA, a similar amphetamine derivative to
methamphetamine, by CB1 receptor stimulation which is
present in striatal medium spiny neurons [44]. All these
receptors are involved in different aspects of learning pro-
cesses [45–47] that became affected by the chronic use of
methamphetamine or MDMA [3, 4, 48, 49].
4. Clinical Toxicology of Methamphetamine
In light of the methamphetamine-induced dopaminergic
neurotoxicity and dopamine loss observed in experimental
animals, it has been speculated for years that metham-
phetamine use may predispose consumers to developing
neurodegenerative disorders like Parkinson’s disease [4, 50,
51]. However, there were no clinical studies proving this
hypothesis until recent epidemiological and neuroimaging
reports. Neuroimaging studies in humans have started to
elucidate the relationship between methamphetamine-abuse
and toxicity and susceptibility to neurodegenerative disorders
[3, 52].
4.1. Neuroimaging Studies in Human Abusers: PET and
MRI Results. Methamphetamine use causes significant long-
term dopaminergic neurotoxicity and neurodegeneration in
human abusers, and these effects persist long after cessation
of drug use. Similar to what has been seen in animal studies,
striatal dopamine levels are reduced by ∼50% in the brains
of human chronic methamphetamine users [52]. Also con-
sistent with animal studies, positron emission tomography
(PET) of methamphetamine abusers revealed persistent and
significant decreases of 20–30% in dopamine transporter
(DAT) in the caudate nucleus and putamen in comparison to
control subjects (see Figure 5).This reduction is evident even
in abusers who had been detoxified for at least 11 months.
Other studies in abstinent former methamphetamine users
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Figure 3: Methamphetamine and MDMA increase the expression of inducible nitric oxide synthase (iNOS) and neuronal nitric oxide
synthase (nNOS) in mouse striatum. Photomicrographs of striatal sections of mice treated with saline or methamphetamine (5mg/kg ×
3) or MDMA (20mg/kg × 3) stained for iNOS and nNOS. Animals were killed 1 day after treatment. Bar indicates 10 𝜇m for iNOS and 50 𝜇m
for nNOS. Modified from Granado et al. [13].
have demonstrated reductions in DAT binding densities
in the striatum as long as 3 years after methamphetamine
withdrawal [53]. This DAT reduction in former addicts has
been associatedwithmotor slowing andmemory impairment
[54–56].
PET studies also found lower densities of serotonin
transporter and vesicular monoamine transporter (VMAT2)
across striatal subregions, midbrain, and hypothalamus of
methamphetamine users [57, 58]. In addition, metham-
phetamine users exhibited increased levels of the lipid per-
oxidation products 4-hydroxynonenal and malondialdehyde
in the caudate and frontal cortex [59] and increased levels of
the antioxidant compoundsCuZnSODand glutathione in the
caudate nucleus [60].
PET studies have revealed that humanmethamphetamine
abusers show prominent microglial activation in the mid-
brain, striatum, thalamus, and orbitofrontal and insular cor-
tices similar to that observed in experimental animals after
methamphetamine treatment, with the magnitude of activa-
tion inversely correlated to duration of methamphetamine
abstinence [61]. Chronic methamphetamine users who died
of drug intoxication showed a significant increase in the
number of microglial cells in the striatum examined by
immunohistochemistry [62]. Intriguingly, several studies
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Figure 4: Metamphetamine produces microglial activation in mouse striatum (Str) but not in nucleus accumbens (NAc). Photomicrographs
of sections of Str and NAcc of mice treated with saline or metahmphetamine (5mg/kg × 3) stained for Mac-1. Animals were killed 1 day after
methamphetamine treatment for Mac-1. Bar indicates 100 𝜇m.
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Figure 5: Reduced DAT function in methamphetamine users. PET images showing accumulation of (11C) WIN-35 428 in the striatum in a
control subject, an abstinent methamphetamine subject, an abstinent methcathinone subject, and a PD patient 70–90min after injection of
(11C) WIN-35 428. Taken fromMcCann et al. [53].
have shown that PD patients have more reactive glial cells
than do patients without the disease, indicating a possible
link between methamphetamine abuse and predisposition to
development of PD [63, 64].
Magnetic resonance imaging (MRI) studies demonstrate
enlarged striatal volumes in adults who recently abstained
from methamphetamine, those with greater cumulative
methamphetamine use or longer duration of use, had smaller
striatal structures that indicate that the pattern of brain
alterations associated with chronic methamphetamine abuse
in humans is consistent with cognitive impairment [57].
Moreover, individuals with smaller striatal volumes also
performed more poorly on several tests that involved exec-
utive function (verbal fluency) and fine motor function
(nondominant grooved pegboard). These findings suggest
that although methamphetamine use may be associated
initially with enlargement of the striatal structures, probably
as a compensatory (inflammatory) response, and preserved
cognitive function, the volumes of the striatum ultimately
decrease with greater methamphetamine usage, accompa-
nied by cognitive impairment. Methamphetamine abusers
have increased brain glucose metabolism in the limbic and
orbitofrontal regions but relative decreases in the striatum
(greater decrease in caudate than in putamen) and in the
thalamus [57]. Reductions in DAT levels in the striatum
and orbitofrontal and dorsolateral prefrontal cortex have
been correlated with the duration of methamphetamine use
and the severity of psychiatric symptoms such as anxiety,
depression, and psychosis [57, 65]. Furthermore, metham-
phetamine abusers show severe gray matter decreases in
cingulate, limbic, and paralimbic cortices [66] and enlarged
striatal volumes [57]. In addition, MR spectroscopy shows
reduced concentrations of a marker of neuronal integrity, N-
acetylaspartate and total creatine in the basal ganglia [57].
All these findings indicate that methamphetamine abuse is
associated with persistent physiologic changes in the human
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brain, similar to those seen in experimental animals, and
that these changes are accompanied by motor and cognitive
deficits [67].
4.2. Motor and Behavioural Deficits in Methamphetamine
Abusers. Although the dopaminergic damage seen in
methamphetamine abuse and PD is similar, the sympto-
matology is largely different. None of the symptoms of
methamphetamine abuse is similar to the clinical features of
Parkinson’s disease; thus, there is no symptomatic reason to
expect that PD will arise due to drug-induced dysfunction
in the dopaminergic system [68]. Although motor deficits
have been reported in chronic methamphetamine abusers,
these deficits do not typically involve gross movements, as
in PD, but rather affect fine motor dexterity, for example,
placing pegs in a pegboard [4, 69]. A plausible explanation
for this lack of immediate parkinsonian symptomatology
was given by Moszczynska et al., [68] who found that
in methamphetamine users, mean dopamine levels were
more reduced in the caudate (−61%) than in the putamen
(−50%), a pattern opposite to that seen in Parkinson’s disease
[70, 71]. Some methamphetamine users had dopamine levels
within the parkinsonian range (up to 97% dopamine loss)
in the caudate but not in the putamen. As the putamen and
caudate subserve aspects of motor and cognitive function,
respectively, the authors suggested that methamphetamine
users were not parkinsonian because dopamine levels are
not sufficiently decreased in the motor component of the
striatum. However, the near-total reduction of dopamine in
the caudate could explain reports of cognitive disturbances,
sometimes disabling, in some drug users [69].
4.3. Increased Risk of Parkinson’s Disease inMethamphetamine
Abusers. Recent publications examining the connection
between methamphetamine abuse and development of PD
indicate a correlation between drug use and later devel-
opment of the disease. Callaghan et al. [72] reported an
increase in incidence of PD in methamphetamine users in
an epidemiological investigation based on data from Cali-
fornia statewide hospital discharge records. They identified
1,863 methamphetamine users, 9,315 patients hospitalized for
appendicitis as a nondrug control group, and 1,720 cocaine
users as a drug control group. All subjects were aged at
least 50 years, had been hospitalized in California between
1990 and 2000, and had been followed for up to 10 years
after discharge. The methamphetamine user group showed
an elevated incidence of PD, with a 165% higher risk for
development of PD than the patients from the control group.
These results have been reproduced later by the same group
[73], using a larger- and more-age-diverse group of patients
(40,000 people hospitalized for methamphetamine versus
200,000 for appendicitis and 35,000 for cocaine) and a
16-year follow-up period. These two studies are the first
to link methamphetamine abuse in young adulthood with
development of PD inmiddle age or later, strongly supporting
that methamphetamine use increases the risk for developing
PD.
5. Conclusions
In experimental animals, exposure to methamphetamine
damages dopaminergic fibres in the striatum and their cell
bodies in the substantia nigra, echoing the degeneration
pattern observed in human patients with PD. Selective
damage to dopaminergic terminals in the striatum has also
been observed in human methamphetamine users, although
there is no evidence so far that methamphetamine damages
dopaminergic cell bodies in the human SNpc. Given these
results, it is reasonable to think that methamphetamine use
may predispose consumers to future development of PD.
This hypothesis has been supported by recent epidemio-
logical work indicating that methamphetamine users have
an increased risk of developing PD. This is consistent with
the persistent neurotoxic effects of methamphetamine in
experimental animals and suggests that methamphetamine
use may also produce irreversible loss of dopaminergic
neurons in the SNpc of human abusers.
PD is a progressive disorder with a presymptomatic
interval; that is, there is a period during which the pathologic
process has begun, but the motor signs required for clinical
diagnosis are absent [51]. Methamphetamine can reduce
dopamine levels in the nigrostriatal system significantly
before motor symptoms become evident, which may explain
whymethamphetamine abusers do not display parkinsonism
in the early stages of drug consumption. Given the large num-
ber of methamphetamine users worldwide, the relationship
between methamphetamine intake and PD could become a
vast public health problem in the future.
Further investigation is needed to elucidate the causes
and mechanisms of methamphetamine-induced damage.
This information will identify mechanisms that might also
be involved in pathology of PD and highlight potential
new therapeutic strategies for prevention or reduction of
dopaminergic neurodegeneration.
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